|
Press Releases |
|
|
|
Monday, March 14, 2022 |
|
IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Approved by FDA |
SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
Thursday, February 17, 2022 |
|
IND Application for SinoMab's First-in-Class Asthma Therapeutic Product SM17 Accepted by FDA |
SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
Wednesday, February 16, 2022 |
|
中国抗体用于哮喘的第一类治疗产品SM17新药研究申请获FDA受理 |
中国抗体制药有限公司(“中国抗体”或“公司”,连同其附属公司,统称“集团”;股份代号:3681.HK),专注研究、发展、制造及商业化免疫性疾病疗法的香港生物制药公司,欣然宣布于二零二二年二月十一日(美国东部当地时间),公司已就用于哮喘的第一类(First-in-Class)治疗产品 SM17 more info >> |
|
中國抗體用於哮喘的第一類治療產品SM17新藥研究申請獲FDA受理 |
中國抗體製藥有限公司(「中國抗體」或「公司」,連同其附屬公司,統稱「集團」;股份代號:3681.HK),專注研究、發展、製造及商業化免疫性疾病療法的香港生物製藥公司,欣然宣佈於二零二二年二月十一日(美國東部當地時間) more info >> |
|
Monday, February 7, 2022 |
|
中国抗体公布SN1011新药研究申请获中国国家药品监督管理局药品审评中心受理 |
中国抗体制药有限公司(“中国抗体”或“公司”,连同其附属公司,统称“集团”;股份代号:3681.HK),专注研究、发展、制造及商业化免疫性疾病疗法的香港生物制药公司,欣然宣布于二零二二年一月二十一日,一项SN1011的新药研究申请 more info >> |
|
中國抗體公佈SN1011新藥研究申請獲中國國家藥品監督管理局藥品審評中心受理 |
中國抗體製藥有限公司(「中國抗體」或「公司」,連同其附屬公司,統稱「集團」;股份代號:3681.HK),專注研究、發展、製造及商業化免疫性疾病療法的香港生物製藥公司,欣然宣佈於二零二二年一月二十一日,一項SN1011的新藥研究申請 more info >> |
|
SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE |
SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, on 21 January 2022, more info >> |
|
Tuesday, January 11, 2022 |
|
中国抗体荣获“第六届金港股”评选中“最佳中小市值公司”、“最佳CEO”奖项及“2021新浪财经金麒麟最佳港美股上市公司”评选中“最具成长潜力上市公司”奖项 |
中国抗体制药有限公司(“中国抗体”或“公司”,连同其附属公司,统称“集团”;股份代号:3681.HK),专注研究、发展、制造及商业化免疫性疾病疗法的香港生物制药公司 more info >> |
|
中國抗體榮獲「第六屆金港股」評選中「最佳中小市值公司」、「最佳CEO」獎項及「2021新浪財經金麒麟最佳港美股上市公司」評選中「最具成長潛力上市公司」獎項 |
中國抗體製藥有限公司(「中國抗體」或「公司」,連同其附屬公司,統稱「集團」;股份代號:3681.HK),專注研究、發展、製造及商業化免疫性疾病療法的香港生物製藥公司 more info >> |
|
SinoMab Awarded the "Best Small and Mid-Cap Company" and "Best CEO" in the Selection of the "6th Hong Kong Golden Stocks Awards" and the "Listed Company with the Most Growth Potential" in the Selection of "2021 Sina Finance Golden Unicorn Best Hong Kong and US Listed Companies" |
SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
国美零售瘦身聚焦主业
Mar 29, 2024 15:20 HKT/SGT
|
|
|
國美零售瘦身聚焦主業
Mar 29, 2024 15:15 HKT/SGT
|
|
|
Gome Retail Streamlines to Focus on Main Business
Mar 29, 2024 15:07 HKT/SGT
|
|
|
国美金融科技公布2023年度业绩
Mar 29, 2024 14:53 HKT/SGT
|
|
|
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical
Mar 29, 2024 15:51 JST
|
|
|
國美金融科技公佈2023年度業績
Mar 29, 2024 14:46 HKT/SGT
|
|
|
Gome Fin Tech Announced Annual Results of 2023
Mar 29, 2024 14:36 HKT/SGT
|
|
|
碧瑶绿色2023年度经调整纯利增加36.7%
Mar 29, 2024 14:26 HKT/SGT
|
|
|
碧瑤綠色2023年度經調整純利增加36.7%
Mar 29, 2024 14:21 HKT/SGT
|
|
|
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture
Mar 29, 2024 15:19 JST
|
|
|
Baguio Green's 2023 Adjusted Net Profit increased by 36.7%
Mar 29, 2024 14:15 HKT/SGT
|
|
|
尚晋国际公布2023年全年业绩
Mar 29, 2024 13:48 HKT/SGT
|
|
|
尚晉國際公布2023年全年業績
Mar 29, 2024 13:38 HKT/SGT
|
|
|
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024
Mar 29, 2024 14:32 JST
|
|
|
Forward Fashion Announced 2023 Annual Results
Mar 29, 2024 13:29 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|